Tillkännagivande • Jun 12
Japan Tissue Engineering Co., Ltd. to Report Q1, 2027 Results on Jul 30, 2026 Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2027 results on Jul 30, 2026 Reported Earnings • May 06
Full year 2026 earnings released: JP¥18.07 loss per share (vs JP¥6.28 loss in FY 2025) Full year 2026 results: JP¥18.07 loss per share (further deteriorated from JP¥6.28 loss in FY 2025). Revenue: JP¥2.18b (down 11% from FY 2025). Net loss: JP¥734.0m (loss widened 188% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Tillkännagivande • May 01
Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026 Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2026. Reported Earnings • Jan 31
Third quarter 2026 earnings released: JP¥4.56 loss per share (vs JP¥3.08 loss in 3Q 2025) Third quarter 2026 results: JP¥4.56 loss per share (further deteriorated from JP¥3.08 loss in 3Q 2025). Revenue: JP¥511.0m (down 6.3% from 3Q 2025). Net loss: JP¥185.0m (loss widened 48% from 3Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. New Risk • Dec 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 02
Second quarter 2026 earnings released: JP¥3.17 loss per share (vs JP¥0.34 loss in 2Q 2025) Second quarter 2026 results: JP¥3.17 loss per share (further deteriorated from JP¥0.34 loss in 2Q 2025). Revenue: JP¥571.6m (down 21% from 2Q 2025). Net loss: JP¥128.6m (loss widened JP¥114.7m from 2Q 2025). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Jul 31
First quarter 2026 earnings released: JP¥5.96 loss per share (vs JP¥5.20 loss in 1Q 2025) First quarter 2026 results: JP¥5.96 loss per share (further deteriorated from JP¥5.20 loss in 1Q 2025). Revenue: JP¥426.0m (down 3.7% from 1Q 2025). Net loss: JP¥242.0m (loss widened 15% from 1Q 2025). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 24
Full year 2025 earnings released: JP¥6.29 loss per share (vs JP¥3.52 profit in FY 2024) Full year 2025 results: JP¥6.29 loss per share (down from JP¥3.52 profit in FY 2024). Revenue: JP¥2.46b (down 2.3% from FY 2024). Net loss: JP¥255.3m (down 279% from profit in FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jun 14
Japan Tissue Engineering Co., Ltd. to Report Q1, 2026 Results on Jul 30, 2025 Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2026 results on Jul 30, 2025 Reported Earnings • May 01
Full year 2025 earnings released: JP¥6.28 loss per share (vs JP¥3.52 profit in FY 2024) Full year 2025 results: JP¥6.28 loss per share (down from JP¥3.52 profit in FY 2024). Revenue: JP¥2.46b (down 2.3% from FY 2024). Net loss: JP¥255.0m (down 278% from profit in FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Apr 30
Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2025 Japan Tissue Engineering Co., Ltd., Annual General Meeting, Jun 19, 2025. New Risk • Apr 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Tillkännagivande • Mar 20
Japan Tissue Engineering Co., Ltd. to Report Fiscal Year 2025 Results on Apr 30, 2025 Japan Tissue Engineering Co., Ltd. announced that they will report fiscal year 2025 results on Apr 30, 2025 Reported Earnings • Feb 01
Third quarter 2025 earnings released: JP¥3.08 loss per share (vs JP¥1.03 loss in 3Q 2024) Third quarter 2025 results: JP¥3.08 loss per share (further deteriorated from JP¥1.03 loss in 3Q 2024). Revenue: JP¥545.0m (up 1.1% from 3Q 2024). Net loss: JP¥125.0m (loss widened 198% from 3Q 2024). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Tillkännagivande • Dec 07
Japan Tissue Engineering Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025 Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2025 results on Jan 31, 2025 Reported Earnings • Nov 02
Second quarter 2025 earnings released: JP¥0.34 loss per share (vs JP¥0.59 loss in 2Q 2024) Second quarter 2025 results: JP¥0.34 loss per share (improved from JP¥0.59 loss in 2Q 2024). Revenue: JP¥718.7m (up 23% from 2Q 2024). Net loss: JP¥13.9m (loss narrowed 42% from 2Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 31
Japan Tissue Engineering Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024 Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2025 results on Oct 31, 2024 Reported Earnings • Aug 01
First quarter 2025 earnings released: JP¥5.20 loss per share (vs JP¥0.32 profit in 1Q 2024) First quarter 2025 results: JP¥5.20 loss per share (down from JP¥0.32 profit in 1Q 2024). Revenue: JP¥442.0m (down 33% from 1Q 2024). Net loss: JP¥211.0m (down JP¥224.0m from profit in 1Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 23
Full year 2024 earnings released: EPS: JP¥3.52 (vs JP¥17.95 loss in FY 2023) Full year 2024 results: EPS: JP¥3.52 (up from JP¥17.95 loss in FY 2023). Revenue: JP¥2.51b (up 24% from FY 2023). Net income: JP¥143.0m (up JP¥872.0m from FY 2023). Profit margin: 5.7% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • May 01
Full year 2024 earnings released: EPS: JP¥3.52 (vs JP¥17.95 loss in FY 2023) Full year 2024 results: EPS: JP¥3.52 (up from JP¥17.95 loss in FY 2023). Revenue: JP¥2.51b (up 24% from FY 2023). Net income: JP¥143.0m (up JP¥872.0m from FY 2023). Profit margin: 5.7% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. New Risk • Apr 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. New Risk • Mar 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Tillkännagivande • Mar 03
Japan Tissue Engineering Co., Ltd. to Report Fiscal Year 2024 Results on Apr 30, 2024 Japan Tissue Engineering Co., Ltd. announced that they will report fiscal year 2024 results on Apr 30, 2024 Reported Earnings • Feb 02
Third quarter 2024 earnings released: JP¥1.03 loss per share (vs JP¥5.02 loss in 3Q 2023) Third quarter 2024 results: JP¥1.03 loss per share (improved from JP¥5.02 loss in 3Q 2023). Revenue: JP¥539.0m (up 14% from 3Q 2023). Net loss: JP¥42.0m (loss narrowed 79% from 3Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Tillkännagivande • Dec 01
Japan Tissue Engineering Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024 Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2024 results on Jan 30, 2024 Reported Earnings • Nov 02
Second quarter 2024 earnings released: JP¥0.59 loss per share (vs JP¥3.77 loss in 2Q 2023) Second quarter 2024 results: JP¥0.59 loss per share (improved from JP¥3.77 loss in 2Q 2023). Revenue: JP¥584.0m (up 6.2% from 2Q 2023). Net loss: JP¥24.0m (loss narrowed 84% from 2Q 2023). Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 9.5% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Tillkännagivande • Sep 01
Japan Tissue Engineering Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023 Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2024 results on Oct 31, 2023 Reported Earnings • Aug 01
First quarter 2024 earnings released: EPS: JP¥0.32 (vs JP¥6.60 loss in 1Q 2023) First quarter 2024 results: EPS: JP¥0.32 (up from JP¥6.60 loss in 1Q 2023). Revenue: JP¥662.0m (up 57% from 1Q 2023). Net income: JP¥13.0m (up JP¥281.0m from 1Q 2023). Profit margin: 2.0% (up from net loss in 1Q 2023). The move to profitability was primarily driven by higher revenue. Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. New Risk • Jul 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Reported Earnings • Jun 18
Full year 2023 earnings released: JP¥17.95 loss per share (vs JP¥12.24 loss in FY 2022) Full year 2023 results: JP¥17.95 loss per share (further deteriorated from JP¥12.24 loss in FY 2022). Revenue: JP¥2.03b (down 3.4% from FY 2022). Net loss: JP¥729.0m (loss widened 47% from FY 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Biotechs industry in Japan. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jun 11
Japan Tissue Engineering Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023 Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2024 results on Jul 31, 2023 Reported Earnings • Apr 29
Full year 2023 earnings released: JP¥17.95 loss per share (vs JP¥12.24 loss in FY 2022) Full year 2023 results: JP¥17.95 loss per share (further deteriorated from JP¥12.24 loss in FY 2022). Revenue: JP¥2.03b (down 3.4% from FY 2022). Net loss: JP¥729.0m (loss widened 47% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Reported Earnings • Jan 28
Third quarter 2023 earnings released: JP¥5.03 loss per share (vs JP¥1.80 loss in 3Q 2022) Third quarter 2023 results: JP¥5.03 loss per share (further deteriorated from JP¥1.80 loss in 3Q 2022). Revenue: JP¥471.4m (down 23% from 3Q 2022). Net loss: JP¥204.3m (loss widened 180% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jan 28
Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023 Japan Tissue Engineering Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales to be JPY 1,971 million. Operating loss to be JPY 787 million. Net loss to be JPY 789 million. Net loss per share to be JPY 19.43. Tillkännagivande • Dec 05
Japan Tissue Engineering Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023 Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2023 results on Jan 31, 2023 Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Toshiyuki Masai was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Nov 01
Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023 Japan Tissue Engineering Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects net sales to be JPY 2,540 million. Operating loss to be JPY 389 million. Net loss to be JPY 388 million. Net loss per share to be JPY 9.57. Reported Earnings • Nov 01
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: JP¥550.2m (up 9.6% from 2Q 2022). Net loss: JP¥153.4m (loss widened 11% from 2Q 2022). Tillkännagivande • Sep 02
Japan Tissue Engineering Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022 Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2023 results at 3:00 PM, Tokyo Standard Time on Oct 31, 2022 Reported Earnings • Jul 28
First quarter 2023 earnings released First quarter 2023 results: Revenue: JP¥422.7m (down 12% from 1Q 2022). Net loss: JP¥268.2m (loss widened 108% from 1Q 2022). Tillkännagivande • Jul 28
Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023 Japan Tissue Engineering Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2023. For the period, the company expected net sales of JPY 2,540 million, operating loss of JPY 389 million, net loss of JPY 388 million and net loss per share of JPY 9.57. Price Target Changed • Jul 23
Price target decreased to JP¥1,200 Down from JP¥1,760, the current price target is provided by 1 analyst. New target price is 95% above last closing price of JP¥615. Stock is down 14% over the past year. The company posted a net loss per share of JP¥12.24 last year. Reported Earnings • Jun 19
Full year 2022 earnings released: JP¥12.26 loss per share (vs JP¥11.48 loss in FY 2021) Full year 2022 results: JP¥12.26 loss per share (down from JP¥11.48 loss in FY 2021). Revenue: JP¥2.10b (down 6.8% from FY 2021). Net loss: JP¥497.9m (loss widened 6.8% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jun 10
Japan Tissue Engineering Co., Ltd. to Report Q1, 2023 Results on Jul 27, 2022 Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2023 results at 3:00 PM, Tokyo Standard Time on Jul 27, 2022 Tillkännagivande • Apr 27
Japan Tissue Engineering Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023 Japan Tissue Engineering Co., Ltd. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of ¥2,540 million, operating loss of ¥389 million and net loss of ¥388 million or ¥9.57 per share. Reported Earnings • Apr 27
Full year 2022 earnings released Full year 2022 results: Revenue: JP¥2.10b (down 6.8% from FY 2021). Net loss: JP¥497.9m (loss widened 6.8% from FY 2021). Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Managing Executive Officer & Director Hiroaki Kaneko was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 08
Japan Tissue Engineering Co., Ltd. to Report Fiscal Year 2022 Results on Apr 26, 2022 Japan Tissue Engineering Co., Ltd. announced that they will report fiscal year 2022 results on Apr 26, 2022 Reported Earnings • Feb 01
Third quarter 2022 earnings: Revenues in line with analyst expectations Third quarter 2022 results: Revenue: JP¥615.5m (up 32% from 3Q 2021). Net loss: JP¥73.6m (loss narrowed 47% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Tillkännagivande • Feb 01
Japan Tissue Engineering Co., Ltd. Announces Earnings Guidance for the Fiscal Year Ending March 31, 2022 Japan Tissue Engineering Co., Ltd. announced earnings guidance for the fiscal year ending March 31, 2022. For the full Fiscal Year, the company expects sales of JPY 2,260 million, Operating loss of JPY 450 million, net loss of JPY 449 million and net loss per share of JPY 11.06. Tillkännagivande • Nov 25
Japan Tissue Engineering Co., Ltd. Announces Start of Clinical Trial for Allogeneic Cultured Epidermis Japan Tissue Engineering Co., Ltd. announced that it submitted notification of the clinical trial plan for Allogeneic Cultured Epidermis (development name: "Allo-JaCE03") to the Pharmaceuticals and Medical Devices Agency today. J-TEC will acquire knowledge and know-how about medical devices through the development of "Allo-JaCE03" and develop new business in fields that use allogeneic cells (cells from other people). With the vision of "creating a future for regenerative medicine", J-TEC is promoting the creation of a regenerative medicine industry and contributing to the improvement of patient quality of life (QOL) by continuously developing and marketing new regenerative medical products and medical devices, in addition to promoting the spread of J-TEC's existing products. " Allo-JaCE03" is dried epidermal cell sheet derived from healthy human skin. Through reconstitution, it returns to the resilient physical properties it had before drying. Its high degree of biocompatibility makes it suitable for use in the promotion of early wound healing. Clinical Trial Summary: The purpose of this clinical trial is to verify the efficacy and confirm the safety of "Allo-JaCE03" in patients with deep dermal burn (DDB), which is a typical skin defect disorder. J-TEC plans to conduct the clinical trial at a total of 5 facilities, including Kyoto University Hospital. Product Features: Because the raw material is allogeneic cells, systematic mass-production of a product that meets certain quality standards is possible. The dried form of this cultured product means that it can be stored at room temperature for long periods of time. Medical institutions can stock it as a ready-made product (one that is manufactured and stored in advance so that it can be used without delay when needed). This product is a medical device that does not contain living cells. J-TEC is taking advantage of the product features of allogeneic origin and dried form to accelerate deployment not only within Japan but also to overseas markets. Reported Earnings • Oct 31
Second quarter 2022 earnings released: JP¥3.40 loss per share (vs JP¥2.41 loss in 2Q 2021) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2022 results: Revenue: JP¥502.0m (down 6.9% from 2Q 2021). Net loss: JP¥138.0m (loss widened 41% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Tillkännagivande • Sep 16
Japan Tissue Engineering Co., Ltd. Announces Approval of Autologous Cultured Oral Mucosal Epithelium Ocural for NHI Listing Japan Tissue Engineering Co., Ltd. announces the approval of Autologous Cultured Oral Mucosal Epithelium "Ocural" for inclusion in the National Health Insurance price list effective December 1, 2021, at the general meeting of Central Social Insurance Medical Council (Chuikyo) held today. Ocural" is expected to be of benefit as a new treatment method for patients who have had marked declines in visual acuity owing to extensive corneal damage from limbal stem cell deficiency. With the corporate vision of "creating a future for regenerative medicine", J-TEC is building a regenerative medicine industry while contributing to the improvement of patients' quality of life (QOL) by continually developing and launching new regenerative medical products in addition to promoting the spread of its existing products. Reported Earnings • Jul 31
First quarter 2022 earnings released The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: JP¥478.3m (up 27% from 1Q 2021). Net loss: JP¥129.5m (loss narrowed 26% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year. Tillkännagivande • Jun 18
Japan Tissue Engineering Co., Ltd. Announces Approval Obtained for Autologous Cultured Oral Mucosal Epithelium “Ocural” Japan Tissue Engineering Co., Ltd. announce that marketing approval was obtained for Autologous Cultured Oral Mucosal Epithelium "Ocural" on June 11, 2021. "Ocural" is a product for the treatment of limbal stem cell deficiency, and it is the world's first regenerative medical product using oral mucosal epithelial cells to treat this disease. This product will be manufactured in Japan and was developed through the practical application of technology developed by Prof. Kohji Nishida of the Department of Ophthalmology, Osaka University Graduate School of Medicine. It will be Japan's second regenerative medical product in the ophthalmology field, following Autologous Cultured Corneal Epithelium "Nepic", for which marketing approval was obtained in March 2020. As the top runner in regenerative medicine in Japan, J-TEC obtained marketing approval for Autologous Cultured Epidermis "JACE", which became Japan's first regenerative medical product, in 2007, and began marketing it in 2009. J-TEC went on to obtain marketing approval for Autologous Cultured Cartilage "JACC" in 2013 and Autologous Cultured Corneal Epithelium "Nepic" in March of 2020. "JACC" and "Nepic" were Japan's first regenerative medical products in the orthopedic surgery and ophthalmology fields, respectively. Through the practical application of "Ocural" in addition to "Nepic", J-TEC has made it possible to provide therapies for corneal epithelial diseases, for which curative treatment methods previously did not exist. J-Tec is promoting the industrialization of regenerative medicine and contributing to the improvement of patients' quality of life (QOL) by further strengthening sales of its existing products and accelerating the development of new regenerative medical products. Tillkännagivande • May 25
Japan Tissue Engineering Co., Ltd. Announces Marketing Approval of Autologous Cultured Oral Mucosal Epithelial Cell Sheet Japan Tissue Engineering Co., Ltd. announced that marketing approval of autologous cultured oral mucosal epithelial cell sheet (Development Name: COMET01) for the treatment of limbal stem cell deficiency (LSCD) *1 has been reviewed and acknowledged at today's meeting of the Regenerative Medical Products and Biological Technology Subcommittee of the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council. COMET01 is epithelial cell sheet derived from human (autologous) oral mucosa. It is prepared by harvesting oral mucosal tissue from the patient and then cultivating the isolated cells. The purpose of this product is to repair defective corneal epithelium by transplanting the sheet onto the ocular surface, where the patient's own oral mucosal epithelial cells become engrafted and epithelialize.
COMET01 is a promising new treatment method for patients who have extensive damage to the cornea of both eyes and markedly reduced visual acuity owing to LSCD. COMET01 was designated a regenerative medical product for orphan diseases *2 -- specifically
the treatment of LSCD -- in 2020. J-TEC introduced the transplantation technique for autologous cultured oral mucosal epithelial cell
sheets developed by Professor Kohji Nishida of Graduate School of Medicine/Faculty of Medicine, Osaka University (Department of Neural and Sensory Organ Surgery (Department of Ophthalmology)) and has taken over the investigator-initiated trial conducted by Professor Nishida's
group, conducting it in the form of a company-sponsored clinical trial of COMET01 since September of 2016. In September of 2020, J-TEC submitted an application for marketing approval of COMET01to the Ministry of Health, Labour and Welfare as Japan's second regenerative medical product in the ophthalmology field. Marketing of COMET01 is to be conducted by Nidek Co., Ltd. (Gamagori City, Aichi Prefecture;
President and CEO, Motoki Ozawa), a maker of ophthalmology and optometry products. As the top runner in regenerative medicine in Japan, J-TEC obtained marketing approval for autologous cultured epidermis "JACE", Japan's first regenerative medical product, in 2007 and
began marketing JACE in 2009. Marketing approval was then obtained for autologous cultured cartilage "JACC" in 2013 and for autologous cultured corneal epithelium "NEPIC" *3 in March of 2020. JACC was Japan's first regenerative medical product in the orthopedic surgery field, and NEPIC was the first in the ophthalmology field. Through the practical application of first NEPIC and then COMET01, J-TEC has succeeded in
providing a treatment method for corneal epithelial diseases for which no curative therapy previously existed. By reinforcing sales of existing products and accelerating development of new regenerative medical products, J-TEC is promoting the development of regenerative medicine into an industry while also contributing to the improvement of patients' quality of life (QOL). Reported Earnings • May 01
Full year 2021 earnings released: JP¥11.48 loss per share (vs JP¥7.07 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: JP¥2.26b (down 2.3% from FY 2020). Net loss: JP¥466.0m (loss widened 62% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Mar 04
New 90-day high: JP¥802 The company is up 24% from its price of JP¥649 on 04 December 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. Reported Earnings • Feb 01
Third quarter 2021 earnings released: JP¥3.40 loss per share (vs JP¥2.24 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥466.4m (down 11% from 3Q 2020). Net loss: JP¥137.9m (loss widened 52% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 63% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 01
New 90-day high: JP¥739 The company is up 12% from its price of JP¥662 on 02 November 2020. The Japanese market is also up 12% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 10.0% over the same period. Tillkännagivande • Dec 19
Japan Tissue Engineering Co., Ltd. to Report Q3, 2021 Results on Jan 29, 2021 Japan Tissue Engineering Co., Ltd. announced that they will report Q3, 2021 results on Jan 29, 2021 Reported Earnings • Nov 01
First half earnings released Over the last 12 months the company has reported total losses of JP¥288.0m, with losses widening by 52% from the prior year. Total revenue was JP¥2.24b over the last 12 months, down 3.2% from the prior year. Tillkännagivande • Sep 06
Japan Tissue Engineering Co., Ltd. to Report Q2, 2021 Results on Oct 30, 2020 Japan Tissue Engineering Co., Ltd. announced that they will report Q2, 2021 results on Oct 30, 2020 Tillkännagivande • Aug 04
Japan Tissue Engineering Co., Ltd. Do Not Provides Earnings Guidance for the Fiscal Year Ending March 31, 2021 Japan Tissue Engineering Co., Ltd. does not provided earnings guidance for the fiscal year ending March 31, 2021. The company announced that the 2019 novel coronavirus infection has spread worldwide and has a great impact on the business environment in Japan and overseas. Since there are many uncertainties that will affect the company's business due to the spread of infection, it is difficult to reasonably calculate the business forecast for the fiscal year ending March 2021 at this point. The company will make an announcement as soon as the situation has settled and it is possible to calculate the earnings forecast. Tillkännagivande • Jun 28
Japan Tissue Engineering Co., Ltd. to Report Q1, 2021 Results on Jul 30, 2020 Japan Tissue Engineering Co., Ltd. announced that they will report Q1, 2021 results on Jul 30, 2020 